Diopter Technologies Completes Early Clinical Study for Innovative Ocular Surface Disease Treatment

Diopter Technologies has announced the completion of early clinical studies for its dissolving amniotic membrane and biopolymer contact lens, a groundbreaking therapeutic device aimed at treating various ocular surface diseases. This innovative lens is designed to release growth factors from amniotic-derived materials while dissolving over 48-72 hours, thereby eliminating the need for clinical removal and reducing the risk of disrupting healing tissues.

The device's key features include sustained growth factor release, a self-dissolving design, and enhanced bioavailability, which collectively aim to reduce scarring and inflammation while promoting epithelial regeneration. Initial clinical studies have shown promising results, with no adverse events reported and increased patient comfort compared to standard silicon hydrogel lenses.

Chris Adams, CEO of Diopter Technologies, highlighted the device's ability to actively deliver healing factors to the ocular surface, marking a shift from passive protection to intelligent tissue remodeling. The lens is currently being studied for multiple indications, including chemical/thermal injury recovery, post-refractive surgery care, and chronic dry eye management, with a planned launch in Q1 2026 following further trials and FDA approval.

This development represents a significant advancement in ocular therapeutic delivery systems, combining advanced materials science with clinical ophthalmology to address a wide range of ocular surface diseases. Diopter Technologies' innovative approach could transform treatment options for patients suffering from these conditions, offering a more effective and convenient solution.